semaglutide or tirzepatide for weight loss Semaglutide/Tirzepatide: Beyond Loss: Shamsah Amersi, MD: OB-GYNs Troubling Findings in Study of

The SURMOUNT trial program provides extensive data on what tirzepatide achieves without any additional weight loss medication: 5 mg dose: 15.0% average weight loss at 72 weeks 10 mg dose: 19.5% average weight loss at 72 weeks 15 mg dose: 20.9% average weight loss at 72 weeks At 15 mg, 56.1% of participants lost at least 20% of body weight At 15 mg, 38.7% of participants lost at least 25% of body weight These numbers are remarkable

Long COVID, studied widely in recent years, also shares common features with these conditions, and this further complicates the landscape, as studies indicate that 2031% of Long COVID patients also meet FM diagnostic criteria 6 months post-infection (Fernndez-de-Las-Peas et al., 2022

This is an effective SHP independent pathway to inhibit CYP7A1 [51, 55, 62]

This drug is a godsend." Anonymous, 68, Female, Oregon 22